Masterclass: DiGa - Entering the digital health space in Germany

The right commercialization model for a digital therapeutic (DTx) product is a key component of success in this rapidly growing space. However, whether you choose a pharma partnership or another popular distribution channel, success is likely to depend on physician awareness of your DTx and their willingness to prescribe or recommend it. Germany’s  Digital Healthcare Act (DVG) and the Digital Health Applications Ordinance (DiGAV) have the potential to play a key role in not only providing a path to reimbursement for digital health applications including DTx, but also for increasing provider awareness and trust in digital therapies. Apps that are approved for the DiGA directory become reimbursable under the German statutory health insurance, making them prescribable to approximately 72.8 million people.